Accurate and timely radiological assessment of solid tumour response to treatment is essential to optimise patient outcomes in oncology. Evaluation of tumour response according to Response Evaluation Criteria In Solid Tumors (RECIST) is constantly performed in clinical trials and more occasionally in routine clinical practice. Radiological reporting is not usually standardised. MIRIO (ON’COHUB), a newly developed tool, streamlines interactions between oncologists and radiologists to optimise and ease response evaluation according to RECIST in routine practice. It applies to reading computed tomography scans and magnetic resonance imaging, and allows switching between evaluation criteria (RECIST 1.1, iRECIST and modified RECIST). MIRIO also provides a standardised radiological report, improving communication between oncology and radiology teams to guide treatment decisions. An ongoing proof-of-concept study is evaluating the feasibility of using MIRIO to assess tumour response according to RECIST in routine clinical practice and identify the benefits it may provide to clinical oncology teams and patients.
Oncologists specialised in sarcomas, breast, lung, colorectal and head and neck cancers, plus radiologists, will use MIRIO to assess tumours at baseline and tumour response according to RECIST for all new patients seen at Centre Léon Bérard, Lyon, France during the study period. Approximately 80 patients in clinical trials and 320 patients in routine clinical practice will be included. Study duration will be 6 months, with the first patients included in March 2018. All investigators will receive training on MIRIO before including patients in the study. A sample of 20 patient records will be peer-reviewed to determine if MIRIO can improve concordance of assessments made by the radiologist and the oncologist. Other outcome measures include assessments of the quality of data in radiology reports with MIRIO versus standard practice, user satisfaction, integration of the tool into routine practice and improvements in therapeutic follow-up for patients.
Clinical trial identification
Legal entity responsible for the study
WeHealth by Servier.
Gail Rickard; Complete HealthVizion.
C. Mastier, C. de la Fouchardière: Medical consulting: Deeplink Medical. All other authors have declared no conflicts of interest.